Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib

Transpl Int. 2011 May;24(5):e43-5. doi: 10.1111/j.1432-2277.2010.01203.x. Epub 2010 Dec 14.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antigens, CD20 / biosynthesis
  • Bone Marrow Cells / cytology
  • Boronic Acids / pharmacology*
  • Bortezomib
  • Graft Rejection
  • Humans
  • Immunity, Humoral
  • Intestines / transplantation
  • Middle Aged
  • Protease Inhibitors / pharmacology*
  • Proteasome Inhibitors*
  • Pyrazines / pharmacology*
  • Salvage Therapy / methods*
  • Short Bowel Syndrome / therapy
  • Syndecan-1 / biosynthesis
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Antigens, CD20
  • Boronic Acids
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Pyrazines
  • Syndecan-1
  • Bortezomib